Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patients
- PMID: 24487271
- PMCID: PMC4046633
- DOI: 10.1097/01.MIB.0000442011.60285.68
Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patients
Abstract
Background: Pyoderma gangrenosum (PG) and erythema nodosum (EN) are the most common cutaneous manifestations of inflammatory bowel disease (IBD) but little is known regarding their etiopathogenesis.
Methods: We performed a case-control study comparing characteristics between IBD patients with a documented episode of PG (PG+) and/or EN (EN+) with those without PG (PG-) and EN (EN-). Data on clinical features were obtained by chart review. IBD-related serology was determined using enzyme-linked immunosorbent assay and genome-wide data generated using Illumina technology. Standard statistical tests for association were used.
Results: We identified a total of 92 cases of PG and 103 cases of EN with genetic and clinical characteristics, of which 64 PG and 55 EN cases were available for serological analyses. Fewer male subjects were identified in the PG(+) (odds ratio 0.6, P = 0.009) and EN(+) groups (odds ratio 0.31, P = 0 < 0.0001). Colonic disease, previous IBD-related surgery, and noncutaneous extra-intestinal manifestations were more common among both PG(+) and EN(+) patients compared with controls. PG(+) was associated with anti-nuclear cytoplasmic antibody seropositivity (P = 0.03) and higher anti-nuclear cytoplasmic antibody level (P = 0.02) in Crohn's disease. Genetic associations with PG included known IBD loci (IL8RA [P = 0.00003] and PRDM1 [0.03]) as well as with USP15 (4.8 × 10) and TIMP3 (5.6 ×10). Genetic associations with EN included known IBD susceptibility genes (PTGER4 [P = 8.8 × 10], ITGAL [0.03]) as well as SOCS5 (9.64 × 10), CD207 (3.14 × 10), ITGB3 (7.56 × 10), and rs6828740 (4q26) (P < 5.0 × 10). Multivariable models using clinical, serologic, and genetic parameters predicted PG (area under the curve = 0.8) and EN (area under the curve = 0.97).
Conclusion: Cutaneous manifestations in IBD are associated with distinctive genetic characteristics and with the similar clinical characteristics, including the development of other extra-intestinal manifestations suggesting shared and distinct etiologies.
Figures
References
-
- Tromm A, et al. Cutaneous manifestations in inflammatory bowel disease. Z Gastroenterol. 2001;39(2):137–44. - PubMed
-
- McCallum DI, Kinmont PD. Dermatological manifestations of crohn's disease. Br J Dermatol. 1968;80(1):1–8. - PubMed
-
- Lindgren A, Wallerstedt S, Olsson R. Prevalence of Crohn's disease and simultaneous occurrence of extraintestinal complications and cancer. An epidemiologic study in adults. Scand J Gastroenterol. 1996;31(1):74–8. - PubMed
-
- Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 1976;55(5):401–12. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- M01-RR00425/RR/NCRR NIH HHS/United States
- DK046763-19/DK/NIDDK NIH HHS/United States
- U01 DK062413/DK/NIDDK NIH HHS/United States
- UL1 TR000124/TR/NCATS NIH HHS/United States
- R01 HS021747/HS/AHRQ HHS/United States
- P01DK046763/DK/NIDDK NIH HHS/United States
- P30 DK063491/DK/NIDDK NIH HHS/United States
- M01 RR000425/RR/NCRR NIH HHS/United States
- AI067068/AI/NIAID NIH HHS/United States
- DK063491/DK/NIDDK NIH HHS/United States
- HS021747/HS/AHRQ HHS/United States
- UL1 TR000124-01/TR/NCATS NIH HHS/United States
- U01 AI067068/AI/NIAID NIH HHS/United States
- P01 DK046763/DK/NIDDK NIH HHS/United States
- DK062413/DK/NIDDK NIH HHS/United States
- U01 DK062420/DK/NIDDK NIH HHS/United States
- U01 DK062431/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials